Galectin Therapeutics Inc. (NASDAQ: GALT), a leading developer of therapeutics targeting galectin proteins, announced its financial results for the quarter ended June 30, 2025. The company reported a net loss applicable to common stockholders of $7.6 million, or ($0.12) per share, compared to a net loss of $12.4 million, or ($0.20) per share, for the quarter ended March 31, 2024. As of June 30, 2025, Galectin Therapeutics had $13.8 million in cash and cash equivalents. Additionally, the company secured a $10 million line of credit in July 2025 to support operations. Research and development expenses decreased significantly to $3.3 million for the quarter ended June 30, 2025, from $9.8 million for the same period in 2024. This reduction is attributed primarily to the timing of expenditures related to the NAVIGATE clinical trial, which concluded in the first quarter of 2025. General and administrative expenses were slightly reduced to $1.4 million for the quarter ended June 30, 2025, compared to $1.5 million for the quarter ended June 30, 2024. The company highlighted ongoing analysis of data from the NAVIGATE trial, which supports the clinical profile of belapectin in patients with MASH cirrhosis. Recent presentations at the European Association for the Study of the Liver (EASL) 2025 Congress and a KOL event in June underscored the potential of belapectin and the relevance of FibroScan® as a predictive biomarker in this context. Galectin Therapeutics believes it has sufficient cash to fund its planned operations and R&D activities through June 30, 2026.